Why the study?
Does urotensin II improve myocardial distensibility in rabbit papillary muscles, and is this effect modulated by angiotensin II or endothelin-1?
Does urotensin II improve myocardial distensibility in rabbit papillary muscles, and is this effect modulated by angiotensin II or endothelin-1?
Urotensin II acutely increases myocardial distensibility in rabbit papillary muscles, an effect that is mediated by the angiotensin II and endothelin-1 systems.
Answers are grounded in this paper and cite their sources.
Does not alter clinical practice; leaves open urotensin II effects on human myocardial compliance.
Endogenous regulators, such as angiotensin-II (AngII), endothelin-1 (ET-1) and urotensin-II (U-II) are released from various cell types and their plasma levels are elevated in several cardiovascular diseases. The present study evaluated a potential crosstalk between these systems by investigating if the myocardial effects of U-II are modulated by AngII or ET-1. Effects of U-II (10(-8), 10(-7), 10(-6) M) were tested in rabbit papillary muscles in the absence and in the presence of losartan (selective AT(1) receptor antagonist), PD-145065 (nonselective ET-1 receptors antagonist), losartan plus PD-145065, AngII or ET-1. U-II promoted concentration-dependent negative inotropic and lusitropic effects that were abolished in all experimental conditions. Also, U-II increased resting muscle length up to 1.008+/-0.002 L/L(max). Correcting it to its initial value resulted in a 19.5+/-3.5 % decrease of resting tension, indicating increased muscle distensibility. This effect on muscle length was completely abolished in the presence of losartan and significantly attenuated by PD-145065 or losartan plus PD-145065. This effect was increased in the presence of AngII, resulting in a 27.5+/-3.9 % decrease of resting tension, but was unaffected by the presence of ET-1. This study demonstrated an interaction of the U-II system with the AngII and ET-1 systems in terms of regulation of systolic and diastolic function.
No takes yet. Share an insight, caveat, or question.
Fontes-Sousa et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: